Ragkun Wart Remover

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. It is imprinted with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Currently, there are no specific indications or usage information provided. Additionally, there are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals are advised to consider the absence of detailed indications when prescribing this medication and to rely on clinical judgment and existing guidelines.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

The medication should be applied by gently squeezing the tube to dispense one drop at a time, ensuring that each wart is sufficiently covered. Following application, the treated area should be allowed to dry.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

For external use only. This product is flammable; therefore, it must be kept away from fire and flame to prevent any risk of ignition.

It is imperative that the product not be applied to irritated skin or any area that is infected or reddened. The use of this product is contraindicated on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Additionally, individuals with diabetes or poor blood circulation should refrain from using this product, as it may pose significant health risks.

Side Effects

Patients should be aware of several important warnings associated with the use of this product. It is intended for external use only and is flammable; therefore, it should be kept away from fire and flame. The product should not be applied to irritated skin or any area that is infected or reddened. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Patients with diabetes or poor blood circulation should not use this product, as it may pose additional risks in these populations.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Ragkun Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the product out of reach of children. It is contraindicated for use on irritated skin or any area that is infected or reddened, including moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes.

In patients with diabetes or poor blood circulation, contact with the eyes should be avoided. If the product inadvertently gets into the eye, it should be flushed with water for 15 minutes. Additionally, inhalation of vapors should be avoided.

Skin discoloration may occur during or after use. The product should be stored at room temperature, avoiding excessive heat (37°C or 99°F). When applying, one drop should be used at a time to sufficiently cover each wart, allowing it to dry. This procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. It is recommended to wipe the tip of the tube with a paper towel between uses to maintain hygiene.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of salicylic acid during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to potential risks to the fetus. Therefore, use during pregnancy should be avoided unless the potential benefit justifies the potential risk to the fetus. Healthcare professionals are advised to carefully consider the risks and benefits when prescribing this medication to pregnant patients or women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the potential risks and benefits.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events were documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important for patients to understand the potential risks associated with improper access to the medication by young individuals. Providers should encourage patients to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the temperature does not exceed 37°C (99°F) to maintain product integrity. Care should be taken to avoid exposure to excessive heat during storage and handling.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Ragkun Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)